Project Grant R44CA291564
Award Date
9/19/24
Completion Date
8/31/26
Dollars Obligated
$2M
Federal Agency
National Cancer Institute
Awardee
Voximetry Inc. (L989DKGM3BU3)
Federal Grant Program
93.394
Assistance Type
Project Grant
Place of Performance
Madison, WI 53717, USA
Similar Awards
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to Radiopharmaceutical Imaging And Dosimetry, LLC provides $1,003,173 to develop a prototype web/cloud-based quantitative SPECT reconstruction software system for clinical trials and dosimetry of radiopharmaceutical therapy (RPT) using alpha-emitting radionuclides. The goal is to create advanced quantitative imaging capabilities to support the precision medicine approach required for...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), provides $1,625,000.00 to Onc.ai, Inc. to develop and validate a radiomics-based multi-modal predictive model for metastatic non-small cell lung cancer patients treated with PD-1 immunotherapy. The key objectives are to: 1) Validate the predictive models in a multi-institutional prospective clinical study, 2) Evaluate the performance characteristics and...
The National Cancer Institute (NCI), under the federal Cancer Biology Research grant program (CFDA 93.396), has awarded a $632,300 Project Grant to Carnegie Mellon University (CMU) to develop an integrated ultra-high-throughput 3D volumetric super-resolution imaging system. This system will combine a multiscale fluorescence mesoscope with magnify expansion microscopy to enable rapid, large-area 3D imaging with exceptional subcellular detail. The goal is to study interactions between cancer and...
This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), provides $399,491 to Northridge Tri-Modality Imaging Inc. to upgrade their gantry-based imaging system to incorporate bioluminescence tomography (BLT) capabilities. The upgraded system will enable 3D whole-body fluorescent, bioluminescent, and anatomical X-ray imaging of small animal cancer models, providing a comprehensive multimodal imaging...
This federal Project Grant award, funded by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), supports the development of an AI-powered system to enhance the detection and tracking of metastatic colorectal cancer using computed tomography (CT) imaging. The $718,456 award, with a project period from July 1, 2025 to May 31, 2029, will enable researchers at the...
The National Cancer Institute (NCI) awarded a $400,000 Project Grant under CFDA 93.394 (Cancer Detection and Diagnosis Research) to O2M Technologies LLC to develop a Multifunctional Imager (MFI) that can simultaneously acquire tissue oxygen pressure (pO2) and pH maps using electron paramagnetic resonance imaging (EPRI) techniques. The 12-month project aims to create a 25 MT Halbach-type permanent magnet, new multi-modal transmit-receive electronics, and the integrated MFI instrument. This...
The National Cancer Institute (CFDA 93.394 Cancer Detection and Diagnosis Research) awarded a $666,670 Project Grant to The Trustees of the University of Pennsylvania, effective January 15, 2025 through December 31, 2028. The goal of this project is to i) develop methods and protocols to obtain high-quality dynamic information from both PET and CT modalities, and ii) use dynamic spectral CT for PET kinetic modeling to reduce overall scan time to match existing clinical PET protocols (~20...
The National Cancer Institute (NCI) awarded a $570,634 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to the University of Connecticut to develop a robust, multimodal, and longitudinal artificial intelligence (AI) system to enhance breast cancer screening. The overarching objective is to optimize and personalize breast cancer screening by advancing AI algorithms that can transform clinical decision-making. The key products/services to be delivered...
This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), provides $549,536 to the Trustees of Dartmouth College to develop an innovative 3D wearable near-infrared (NIR) spectral tomography system. The objective is to create a clinical platform capable of early prediction of residual cancer burden in breast cancer patients undergoing neoadjuvant chemotherapy. The proposed technological innovations focus...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $658,336 to Rarecyte, Inc. to develop the ORION2 instrument, a system that will enable highly multiplexed spatial profiling of tumor and tissue samples. The key products and services to be delivered under this 3-year award (June 2025 - May 2028) include: Developing an automated imaging system with adaptive controls to balance speed of data acquisition and image...